

Eric de La Fortelle, PhD, MBA



Eric is a Venture Partner with Seventure Partners, a Paris-based venture capital investor investing broadly in life sciences (Rx, Dx, medical device) with a specific focus on the human microbiome. Seventure has raised the two first fund worldwide dedicated to the microbiome, called Health for Life 1 and Health for Life 2, respectively in 2013 and 2019. Eric sits on the Board of directors of Mint Solutions BV, Maat Pharma SA, TargEDys SA, Anaeropharma Ltd. (observer), BiomX Ltd., DayTwo Ltd. (Observer), A-Mansia SA, NeurIMM SA, Siolta Therapeutics, Inc (observer) and Axial Biotherapeutics as a representative for Seventure, and of Sensorion SA as an independent director.

Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche's global function of External Research and Technologies. In this role, he had a dual mandate of BD&L (finding partners, negotiating contracts, managing alliances), leading to more than 200 deals being signed ; and strategic advisory (R&D scenarios for a 2-years horizon and actionable recommendations).

Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, a post-graduate diploma in biomedicine from IFSBM (Institut Gustave-Roussy), and an MBA (honors) from INSEAD.